Home › NDC Lookup › RxCUI directory › RxCUI 2375141

15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Fasp... — RxCUI 2375141

RxNorm drug concept · Semantic branded drug
RxCUI 2375141 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2375141
Official name15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asDARZALEX Faspro 1800 MG / 30,000 UNT per 15 mL Injection; DARZALEX Faspro 1800 MG / 30,000 UNT in 15 mL Injection; DARZALEX Faspro (daratumumab-hyaluronidase-fihj 1800 MG /30,000 UNT) per 15 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)24,846 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Daratumumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Darzalex is a type of targeted therapy called a monoclonal antibody. It works by homing in on a protein called CD38 that sits on the surface of myeloma cells. Once it locks on, it...
  • What exactly is Darzalex and what is it supposed to do for my myeloma?
  • No, Darzalex can't be taken at home. It's given as an IV infusion through a vein, always in a clinic or infusion center by trained healthcare staff. That's because there's a risk o...
  • How will I get this medication — do I take it at home?
📖 Read our full Daratumumab Injection guide →

🕸️ Concept Web — How 15 ML daratumumab-fihj 120 MG/ML / hyaluronidase... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro] RxCUI 2375141

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Daratumumab 1721947
    • Hyaluronidase 5464
    • Daratumumab / hyaluronidase 2372199
    • Daratumumab-fihj 2375130
    • Hyaluronidase-fihj 2375132
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Darzalex Faspro 2375137
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Daratumumab / hyaluronidase Injection 2375135
    • Daratumumab-fihj / hyaluronidase-fihj Injection 2649490
    • Daratumumab / hyaluronidase Injectable Product 2375134
    • Daratumumab-fihj / hyaluronidase-fihj Injectable Product 2660319
    • Daratumumab / hyaluronidase Injection [Darzalex Faspro] 2375139
    • Daratumumab-fihj / hyaluronidase-fihj Injection [Darzalex Faspro] 2655021
    • Darzalex Faspro Injectable Product 2375140
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection SCD · 2375136
  • Daratumumab-fihj 120 MG/ML SCDC · 2375131
  • Hyaluronidase-fihj 2000 UNT/ML SCDC · 2375133
  • Daratumumab / hyaluronidase Injection SCDF · 2375135
  • Daratumumab-fihj / hyaluronidase-fihj Injection SCDFP · 2649490
  • Daratumumab / hyaluronidase Injectable Product SCDG · 2375134
  • Daratumumab-fihj / hyaluronidase-fihj Injectable Product SCDGP · 2660319

Brand-Name Concepts

  • Daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro] SBDC · 2375138
  • Daratumumab / hyaluronidase Injection [Darzalex Faspro] SBDF · 2375139
  • Daratumumab-fihj / hyaluronidase-fihj Injection [Darzalex Faspro] SBDFP · 2655021
  • Darzalex Faspro Injectable Product SBDG · 2375140
  • Darzalex Faspro BN · 2375137

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2375141 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
57894-0503-01 1 VIAL, SINGLE-DOSE in 1 BOX (57894-503-01) / 15 mL in 1 VI... Darzalex Faspro Janssen Biotech, Inc. 2020-05-01
Observed labelers: Janssen Biotech, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9144 Daratumumab, hyaluronidase 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.